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François Amalric, Luc Sensébé, Anne Gonzalez-de-Peredo, Isabelle Ader, Odile Burlet-Schiltz,
and Marie-Pierre Bousquet
Correspondence
odile.schiltz@ipbs.fr;
marie-pierre.bousquet@ipbs.fr
In Brief
20S proteasomes are very heter-
ogeneous protein complexes in-
volved in many cellular pro-
cesses. In the present study, we
combined an MRM-based assay
with the production and purifica-
tion of entire SILAC labelled pro-
teasome to monitor absolute
quantities of the different 20S
proteasome subtypes in various
human cells and tissues. This
method applied to adipocyte-
derived stem cells (ADSCs) ampli-
fied under various conditions
highlights an increased expres-
sion of immunoproteasome when
this type of cell is primed with
IFN or amplified in a 20% O2
environment.
Graphical Abstract
Highlights
• Design of an MRM assay to determine the absolute quantity and stoichiometry of ubiquitous and
tissue-specific human 20S proteasome subtypes.
• Use of purified isotopically labelled 20S proteasome as internal standard for accurate quantification.
• Variation in the expression of immunoproteasome in adipocyte-derived stem cells (ADSCs) grown
under different O2 levels might be causal for change in cells differentiation capacity.
• The status of 20S proteasome during ADSCs expansion might constitute an additional relevant quality
control parameter to contribute to predict, among other quality markers, their therapeutic capacity.
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Mathilde Beau‡, Marie-Laure Renoud§, François Amalric‡, Luc Sensébé§,
Anne Gonzalez-de-Peredo‡, Isabelle Ader§, Odile Burlet-Schiltz‡¶,
and Marie-Pierre Bousquet‡**
The proteasome controls a multitude of cellular pro-
cesses through protein degradation and has been identi-
fied as a therapeutic target in oncology. However, our
understanding of its function and the development of spe-
cific modulators are hampered by the lack of a straight-
forward method to determine the overall proteasome
status in biological samples. Here, we present a method
to determine the absolute quantity and stoichiometry of
ubiquitous and tissue-specific human 20S proteasome sub-
types based on a robust, absolute SILAC-based multiplexed
LC-Selected Reaction Monitoring (SRM) quantitative mass
spectrometry assay with high precision, accuracy, and sen-
sitivity. The method was initially optimized and validated by
comparison with a reference ELISA assay and by analyzing
the dynamics of catalytic subunits in HeLa cells following
IFN-treatment and in range of human tissues. It was then
successfully applied to reveal IFN- and O2-dependent vari-
ations of proteasome status during primary culture of Adi-
pose-derived-mesenchymal Stromal/Stem Cells (ADSCs).
The results show the critical importance of controlling the
culture conditions during cell expansion for future thera-
peutic use in humans. We hypothesize that a shift from the
standard proteasome to the immunoproteasome could
serve as a predictor of immunosuppressive and differenti-
ation capacities of ADSCs and, consequently, that quality
control should include proteasomal quantification in addi-
tion to examining other essential cell parameters. The
method presented also provides a new powerful tool to
conduct more individualized protocols in cancer or in-
flammatory diseases where selective inhibition of the
immunoproteasome has been shown to reduce side
effects. Molecular & Cellular Proteomics 18: 744–759,
2019. DOI: 10.1074/mcp.RA118.000958.
Some hematopoietic malignancies can be successfully
treated by inhibition of the catalytic core 20S proteasome
complex, and more recent findings indicate that the protea-
some is a promising target for the treatment of other cancer
types or other pathologies including inflammatory diseases
(1–3).
Although the cylindrical 7777 barrel-like structure
of the 20S catalytic core proteasome has been preserved
throughout evolution, the oligomeric protease has evolved,
resulting in a higher heterogeneity of subunit compositions in
mammals. As schematically represented in Fig. 1A, there exist
at least six distinct forms of 20S proteasomes in human cells
and tissues. The standard 20S proteasome (sP20S)1 is com-
posed of constitutive (1–7 and 3, 4, 6, and 7) and
catalytic subunits (1, 2, and 5). It is the most abundant
20S subcomplex in most cell types, but significant amounts of
other 20S forms have been observed in some human tissues
and cells in their basal state or are induced in specific envi-
ronmental conditions (4). For instance, in response to pro-
inflammatory cytokines or in immune cells, the three catalytic
subunits of the sP20S can be replaced in a highly regulated
way by their immuno counterparts to form the immunopro-
teasome (iP20S), which has nonidentical cleavage specifici-
ties (5). Two intermediate proteasomes harboring a mixed
assortment of standard and immunocatalytic subunits (1i
P20S, 1i5i P20S) have also been observed in various hu-
man tissues and cells, and their existence is consistent with
the rules of cooperative assembly of inducible catalytic sub-
units (6). Some other 20S subtypes are much more tissue-
specific, such as the thymoproteasome (containing 1i, 2i
and 5t catalytic subunits) and the spermatoproteasome
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(containing a specific isoform of 4 called 4s) which are
found in the thymus and male germ cells, respectively. The
environment- or tissue-specific subunit composition of hu-
man 20S proteasome has been shown to fulfill specialized
functions that the standard proteasome can only exert sub-
optimally (4). For example, immune cells contain a significant
proportion of immunosubunit-containing 20S proteasome
subtypes which display specific proteolytic preferences
thanks to which they produce antigens for presentation to
CD8 T cells (6). In the thymus, the unique cleavage preference
of 5t explains the essential role played by the thymoprotea-
some in the positive selection of developing T lymphocytes
(7). Thus, knowledge of 20S proteasome composition will help
us to better understand proteasome function in a given tissue
or cell type. It is also crucial when developing novel therapeu-
tic strategies targeting specific 20S proteasome variants. In-
deed, the immunoproteasome is a valuable target in several
ongoing oncology trials as well as in the treatment of inflam-
matory and autoimmune diseases (2, 3, 8). Thus, to assess
proteasome status, by determining the absolute quantity and
stoichiometry of all subtypes, precise and accurate absolute
quantification of several subunits from the same biological
sample is required. As mRNA and protein levels reported from
proteomic and transcriptomic analyses show a low correlation
(9), quantification must be performed at the protein level to
allow an accurate and complete description of the 20S pro-
teasome status. Several ELISA protocols have been pub-
lished or are commercially available to determine absolute
levels of both 20S and 26S proteasome complexes, but only
at the global level, i.e. they make no distinction between the
different subcomplexes (6, 10–14). Only Guillaume et al. (6)
considered the heterogeneity of 20S subtypes when develop-
ing their ELISA assay by using different in-house produced
antibodies directed against four different standard and immu-
nocatalytic  subunits. More recently, standard and immuno-
proteasome subtypes were determined by surface plasmon
resonance imaging (SPRI) using specific inhibitors (15). How-
ever, the multiplexing capacity of these methods is insufficient
to fully assess proteasome heterogeneity in a single assay.
To overcome this limitation, we propose to use Selected
Reaction Monitoring (SRM), an isotope dilution mass spec-
trometry (IDMS)-based technique which has been approved
for the quantification of multiple biomolecules. In addition to
its robustness, precision and accuracy, the main advantage of
SRM is its capacity to quantify many analytes simultaneously.
SRM has recently been successfully applied in protein assays
(16, 17). In these studies, the proteins themselves were not
directly detected and quantified, but were analyzed at peptide
level, after enzymatic proteolysis. This is a critical step be-
cause, in most cases, the absolute quantification relies on the
addition of an isotopically-labeled peptide standard (called
AQUA peptide) (18) late in the experimental workflow, which
might introduce a high variability because of differences in
sample preparation. Thus, for accurate and robust absolute
quantification of proteins, and to determine protein stoichi-
ometry within protein complexes, the use of isotope-labeled
peptides as internal standards requires careful optimization of
experimental conditions (19). An alternative approach based
on artificial genes coding for concatenated proteotypic pep-
tides (QconCAT strategy) (20) may be used to decrease quan-
tification biases. For robust absolute quantification, an iso-
tope-labeled equivalent of the full-length target protein is
considered the ideal internal standard. Several approaches
based on the synthesis of heavy versions of the protein of
interest have emerged recently. Most of them rely on meta-
bolic labeling and purification of a recombinant version of the
protein of interest, or a shorter specific protein sequence, like
the Protein Standards for Absolute Quantification (PSAQ) (21),
absolute SILAC (22), PrEST (23), FlexiQuant (24), and TAQSI
(25) methods. Another approach consisting in the chemical
labeling of proteins using isobaric stable isotope tagging
technology (26) has recently been described to reduce costs
and the time required to grow cells in heavy amino acid-
containing media. In all these approaches, because the inter-
nal standard is processed together with its endogenous ana-
log throughout the whole workflow, accuracy is markedly
better than achievable with AQUA and QconCAT approaches
when determining absolute quantities of proteins in various
matrices (17). However, to our knowledge, the absolute quan-
tification relying on the isotopic dilution of labeled proteins
has been limited so far to monomers, and no reports of assays
to determine the stoichiometry of macromolecular complexes
have been published.
Mesenchymal stem/stromal cells (MSC) hold great potential
in regenerative medicine because of their multi/pluripotency
and immunosuppressive properties. Over the last decade, the
clinical use of MSC has rapidly increased, and more than 800
clinical trials assessing MSC therapy in multiple clinical set-
tings are currently registered (https://www.clinicaltrials.gov/).
Adipose-derived Stem Cells (ADSCs) are a subclass of mes-
enchymal stem/stromal cells initially derived from the bone
marrow. However, to obtain the critical number of cells before
transplantation, ADSCs must be expanded in vitro. This es-
sential step has raised important concerns about the quality
of adult stem cells, and interpatient variability is a challenge
when seeking to define ADSCs. The development of uniform
protocols for both preparation and characterization of MSCs,
including standardized functional assays to assess their bio-
1 The abbreviations used are: sP20S, standard 20S proteasome;
iP20S, immunoproteasome; 5t P20S, thymoproteasome; 4s P20S,
spermatoproteasome; ADSCs, Adipose-derived Mesenchymal Stro-
mal/Stem Cells; AT, Adipose Tissue; CID, Collision Induced Dissoci-
ation; FBS, Fetal Bovine Serum; IDMS, Isotope Dilution Mass Spec-
trometry; IFN, interferon ; vMSCs, Mesenchymal Stem Cells;
SILAC, Stable Isotope Labeling by Amino acids in Cell culture; SRM/
MRM, Single Reaction Monitoring/Multiple Reaction Monitoring; SVF,
Stromal vascular fraction.
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logical potential, will be critical in contributing to their clinical
utility.
Here, we applied the SILAC method to engineered cell lines
expressing either the standard 20S proteasome or the immu-
noproteasome to produce and purify isotope-labeled, endog-
enous versions of standard proteasome and immunoprotea-
some in vivo. These isotope-labeled proteasome complexes
were used as internal standards to quantify the absolute
concentration of all 20S catalytic and noncatalytic subunits in
biological samples of various origins. The method developed
was applied to determine the absolute concentration of total
20S proteasomes and the exact stoichiometry of six ubiqui-
tous and tissue-specific 20S proteasome subtypes in a mul-
tiplexed LC-SRM assay with high precision (92%), accuracy
(90%), and sensitivity (1 fmol on column). Our results
show that the absolute quantity and stoichiometry of the
proteasome are challenged both by IFN stimulation and O2
levels during ex vivo expansion of primary ADSCs. Thus,
determining proteasome status, which is a central contributor
to maintaining stem cell homeostasis—characterized by
stemness, capacity for self-renewal and cell differentiation
(27–29)—might constitute an additional relevant quality con-
trol parameter for the production of ADSCs for clinical appli-
cations, which is of interest as the number of quality markers
currently available is limited (30). Furthermore, accurate and
precise assessment of proteasome abundance and heteroge-
neity could also help when seeking to achieve selective inhi-
bition of a proteasome subtype, like the immunoproteasome,
for personalized therapies in cancer or autoimmune diseases.
This is the first study to report the simultaneous determination
of absolute quantity and stoichiometry for macromolecular
complexes based on the isotopic dilution of labeled proteins
in numerous human tissues and primary ADSCs culture.
EXPERIMENTAL PROCEDURES
Cell Lines, Culture Conditions, SILAC, Human Samples—HEK
293T, HCT116, HeLa, and RKO cell lines were grown in DMEM
medium supplemented with 10% fetal bovine serum (FBS). U937,
HeLa S3, and NB4 cell lines were grown in RPMI 1640 medium
supplemented with 10% FBS. KG1a cell line was grown in RPMI 1640
medium supplemented with 20% FBS. MRC5 cell line was grown in
MEM- medium supplemented with 10% FBS. All cultures were
supplemented with 2  103 M glutamine, 100 units/ml penicillin, 100
g/ml streptomycin, and maintained at 37 °C under 5% CO2. Unsyn-
chronized cells were harvested at 80% confluence for adherent cells
or at a concentration of 1106 cells per ml of culture for suspension
cells. HeLa cells were treated with interferon- (R&D Systems, Min-
neapolis, MN) at 100 ng/ml in fresh medium.
Human 293-EBNA cells, “HEK-EBNA sP20S” (mainly expressing
sP20S), and 293-EBNA cells engineered to express iP20S, “HEK-
EBNA iP20S” (by transfecting 293-EBNA cells with cDNAs encoding
the three immunocatalytic subunits 5i, 1i and 2i) were obtained as
previously described (6). HEK-EBNA sP20S cells were cultured in
SILAC medium which is composed of DMEM supplemented with
10% dialyzed FBS, 4 mM L-glutamine, 200 mg/L L-Proline, 100 mg/ml
L-arginine (13C6), and L-lysine (
13C6) (Cambridge Isotope Lab., Tewks-
bury, MA), 100 IU/ml penicillin and 100 g/ml streptomycin in 150
cm2 culture plates and maintained at 37 °C under 5% CO2. HEK-
EBNA iP20S were cultured in the same SILAC medium as HEK-EBNA
sP20S, but further supplemented with 5 g/ml Puromycin and 600
g/ml Hygromycin to maintain selective pressure. Ten cellular dou-
blings were performed in this medium to achieve an incorporation rate
of 95% heavy amino acids in proteins (assessed by MS). Standard
20S proteasome and iP20S were then purified as described earlier
(31). Absolute quantities and purities of both purified proteasome
subtypes were then assessed as described in Supplementary infor-
mation I-1. Isotope-labeled sP20S and iP20S were stored as 10-l
aliquots at 1.158 and 0.980 pmol/l, respectively, in 20 mM Tris/HCl,
pH 7.2, 1 mM EDTA, 1 mM DTT, 10% glycerol, and at 80 °C to
ensure stability over time.
Whole-cell lysates from various human tissues were supplied by
AMSBio (Cambridge, MA) (HT-201 (Brain); HT-311 (Colon); HT-804
(Heart); HT-314 (Liver); HT-601 (Lung); HT-406 (Ovary); HT-102 (Skel-
etal muscles); HT-701 (Spleen); HT-401 (Testis); HT-704 (Bone Mar-
row); P1234264 (Thymus)).
Human ADSC were isolated from subcutaneous adipose tissue
(AT) obtained from nonobese human donors (body mass index 26)
undergoing elective abdominal dermolipectomy (Plastic Surgery De-
partment, Rangueil Hospital, Toulouse, France). No-objection certifi-
cates were obtained to comply with bioethics law no. 2004–800 of 6
August 2004. The stromal vascular fraction (SVF) was obtained by
enzymatic digestion of adipose tissue (AT) with collagenase NB4
(Roche Diagnostics, Indianapolis, IN). Cells were then seeded at 4000
cell/cm2 (P0) and cultivated in -minimal essential medium supple-
mented with 10% FBS (Gibco), 100 g/ml streptomycin, 100 U/ml
penicillin, 25 g/ml amphotericin (Thermo Fisher Scientific Life Sci-
ences, Waltham, MA). Medium was changed twice a week. Cells from
the same patients were cultured under normoxic (20% O2, 5% CO2)
or hypoxic (1% or 5% O2, 5% CO2) conditions in an Xvivo System
(BioSpherix, Paris, NY) to maintain cells in hypoxic conditions at all
culture steps. Interferon- (100 ng/ml) was added to the medium in
some experiments.
Our experimental protocols were approved by French research
ministry’s institutional ethics committee of (N°: DC-2015-23-49) and
informed consent was obtained from all subjects in line with current
regulations (no subjects age under 18 were included).
Adipocyte Differentiation—ADSCs obtained from patients were
seeded at 20,000 cell/cm2 and were exposed to an adipogenic mix-
ture containing IBMX (3-isobutyl-1-methylxanthine) 0.45 mM, Dexam-
ethazone 1 M and Indomethacine 60 M. An immunoproteasome
inhibitor, 100 nM ONX-0914 (solubilized in 0.001% DMSO), was also
added to the cell medium in some conditions; 0.001% DMSO was
added to the control condition in these cases. Cells were grown at
37 °C under normoxic (20% O2) or hypoxic conditions (5% and or 1%
O2). The medium was changed every 2–3 days throughout the culture
process. At the end of experiment, the cell lineage was determined
using Oil Red O which stains for adipocytes.
20S Proteasome Purification—When they reached 80% conflu-
ence, HEK-EBNA cell lines (HEK-EBNA sP20S or HEK-EBNA iP20S)
were harvested in HKMG buffer (10 mM Hepes pH 7.9, 10 mM KCl, 5
mM MgCl2, 10% glycerol, 10 mM ATP, 1% NP40, protease and
phosphatase inhibitor (Roche, Bâle, Switzerland)) and centrifuged for
10 min at 10,000  g. Supernatants were kept and used for protea-
some immuno-purification as previously described (31).
ELISA-based Absolute Quantification of the 20S Proteasome—
ELISA-based absolute quantification of the 20S proteasome was
performed as previously described (14). Briefly, ELISA assays were
performed in 96-well plates (IMMULON HBX 4, Thermo Scientific).
The plate was coated with 100 l MCP21 monoclonal antibody (Eu-
ropean Collection of Cell Cultures) at 5 g/ml by incubation at 4 °C
overnight. Wells were then washed 3 times with PBS/T-buffer. Non-
specific sites were blocked by incubation with 2% BSA in PBS for 1 h
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at room temperature with slow shaking. The plate was washed 3
times with PBS/T-buffer. The samples (cell lysates) were then depos-
ited in triplicate and incubated for 2 h at room temperature. The plate
was washed with PBS/T-buffer and then incubated with the poly-
clonal rabbit anti-20S antibody (PW 8155, ENZO LIFE Sciences,
Farmingdale, NY) for 1 h at room temperature under slow shaking.
The plate was washed 3 times with PBS/T-buffer and antibody bind-
ing was revealed using horseradish peroxidase-conjugated anti-
rabbit antibody and 2 mg/ml ABTS substrate (2,2-azino-bis(3-ethyl-
benzthiazoline-6-sulfonic acid)). The reaction was monitored by
measuring the optical density at 416 nm (Quant; Bio-Tek instru-
ments, Inc., Winooski, VT). The amount of proteasome in the sample
was calculated by comparison with the calibration curve produced
with purified 20S proteasome purified from human erythrocytes
(ENZO LIFE SCIENCE). A linear dose-response was observed be-
tween 0 and 20 ng.
Proteasome Activity Assay—Cultured cells were harvested in
HKMG buffer and sonicated in ice with a Bioruptor Plus (Diagenode,
Liège, Belgium) (15 min, cycle 45 s/15 s (ON/OFF), position High).
Protein concentration was determined by detergent-compatible pro-
tein assay (DC Assay - BioRad, Hercules, CA) according to the
manufacturer’s recommendation. Proteasome activity was assayed in
96-well black plates (Greiner Bio-One, Frickenhausen, Germany). 10
l of each lysate fraction were added to 40 l of Tris-HCl 100 mM and
50 l of Suc-LLVY-AMC (for chymotrypsin-like activity), Boc-LRR-
AMC (for trypsin-like activity) and Z-LLE-AMC (for PGPH activity)
substrate in 200 mM Tris-HCl, pH 8 (Enzo Life Science) at a final
concentration of 400 M/well. Kinetic assays were performed at 37 °C
in a FLX-800 spectrofluorometer (BIOTEK) over 90 min, reading flu-
orescence every 5 min, at 460 nm following excitation at 360 nm.
Samples Preparation and In-gel Digestion for Mass Spectrometry
Analysis—Samples were heated to 95 °C for 5 min in Laemmli buffer
to denature proteins; 100 mM chloroacetamide was then added to the
sample followed by incubation for 30 min at room temperature in the
dark. Proteins were loaded onto a 12% acrylamide SDS-PAGE and
concentrated in a single band, visualized by Coomassie staining
(Instant Blue - Expedeon). The gel band containing the whole sample
was cut and washed several times in 50 mM ammonium bicarbonate,
acetonitrile (1:1) for 15 min at 37 °C. Trypsin (Promega) digestion was
performed over night at 37 °C in 50 mM ammonium bicarbonate at a
trypsin/total protein ratio of 1/50. Peptides were extracted from the
gel by two incubations in 10% formic acid, acetonitrile (1:1) for 15 min
at 37 °C. Extracts were dried in a SpeedVac, and resuspended in 2%
acetonitrile, 0.05% trifluoroacetic acid prior to LC-MS/MS analysis.
For LC-SRM analysis, 1 pmol of labeled iP20S and 1 pmol of
labeled sP20S were added to 25 g of total proteins before the
protein denaturation step. When used, AQUA peptides (Thermo Sci-
entific Pierce Protein Research) were spiked into samples just before
mass spectrometry analysis at a concentration resulting in injection of
a final quantity of 70 fmol.
Whole Proteome Analysis of Extracts from Human Tissues and
Adscs Grown Under Normoxic and in Hypoxic Conditions (1% O2)—
Peptide mixtures were analyzed by nano-LC-MS/MS using an Ulti-
mate3000 system (Dionex Sunnyvale, CA) coupled to an LTQ-Or-
bitrap Velos mass spectrometer (Thermo Fisher Scientific) when
analyzing human tissue extracts or to a Q-Exactive Plus mass spec-
trometer (Thermo Fisher Scientific) when analyzing ADSCs. Five mi-
croliters (human tissue) or two microliters (ADSCs) of each peptide
sample at 1 g/l were loaded onto a C18 precolumn (300 m inner
diameter  5 mm; Thermo Scientific) at 20 l/min in 5% acetonitrile,
0.05% trifluoroacetic acid. After 5 min of desalting, the precolumn
was switched online with the analytical C18 column (75 m inner
diameter x 50 cm; home-made) equilibrated in 95% solvent A (5%
acetonitrile, 0.2% formic acid) and 5% solvent B (80% acetonitrile,
0.2% formic acid). Peptides from human tissues were eluted using a
5–50% gradient of solvent B over 105 min at a flow-rate of 300 nL/min
and peptides from ADSCs were eluted using a 5–25% gradient of
solvent B over 165 min and a 25–50% gradient of solvent B over 135
min at a 300 nl/min flow rate. Both mass spectrometers were oper-
ated in data-dependent acquisition mode. During the analysis with
the LTQ-Orbitrap Velos, survey scan MS spectra were acquired in
the Orbitrap over the 350–1800 m/z range with resolution set to
60,000 (these parameters were 350–1500 m/z and 70,000 with
Q-Exactive Plus, respectively). On the LTQ-Orbitrap Velos, the
twenty most intense ions per survey scan were selected for CID
fragmentation, and the resulting fragments were analyzed in the
linear trap (LTQ). On the Q-Exactive Plus, the ten most intense ions
per survey scan were selected for HCD fragmentation, and the
resulting fragments were analyzed in the Orbitrap. Dynamic exclu-
sion was used with a 60-s or a 30-s window (on the LTQ-Orbitrap
Velos or the Q-Exactive Plus, respectively) to prevent repeated
selection of peptides.
Raw mass spectrometry files were processed using MaxQuant
(version 1.5.5.1) and Andromeda was used to match MS/MS spectra
against the Human SwissProt database (March 2017 release - 20,181
entries for human tissues analysis/release of August 2018 - 20,386
entries for ADSCs analysis) and a list of potential contaminant se-
quences provided in MaxQuant1.5.5.1., with Carbamidomethylation
of cysteines set as fixed modification. Oxidation of methionine and
protein N-terminal acetylation were set as variable modifications. The
digestion specificity of trypsin was defined as cleavage after K or R,
and up to two missed trypsin cleavage sites were allowed. The
precursor mass tolerance was set to 20 ppm for the first search and
4.5 ppm for the main search. The mass tolerance in MS/MS mode
was set to 0.8 Da for tissue analysis and to 20 ppm for ADSC analysis.
Minimum peptide length was set to seven amino acids, and minimum
number of unique peptides was set to 1. A target-decoy approach
was used to validate hits, using a reverse database and applying a
peptide and protein false-discovery rate of 1%. The “match between
runs” option in MaxQuant was enabled, with a time window of 0.7
min, to allow cross-assignment of MS features detected in different
runs. Only unique peptides were used for quantification when ana-
lyzing human tissues, whereas both unique and razor peptides were
used for the quantification when dealing with ADSCs data. Quantita-
tive proteomic analysis was performed on the normalized LFQ inten-
sities from the “proteinGroups” Table in the MaxQuant output. Protein
entries identified as potential contaminants by MaxQuant were elim-
inated from the analysis, as were proteins identified by fewer than two
peptides. Tissue-specific 20S proteasome subunits (4s, 1i, 2i,
5i, and 5t) were compared across the different tissues based on
their normalized LFQ intensities (Fig. 3B). To compare the proteomes
of ADSCs grown under normoxic or hypoxic conditions, the LFQ
intensity values were used for the quantitative analysis. Fold-changes
were log2 transformed and thresholds calculated based on their dis-
tribution. The upper threshold was calculated as Q3  1.5  IQ, and
the lower threshold as Q1  1.5IQ, where IQ is the interquartile, and
Q1 and Q3 are the first quartile and the third quartile, respectively.
Proteins with fold-changes outside these thresholds were considered
outliers from the global distribution. Outlier proteins with a p value of
less than 0.05 were considered as differentially expressed between
normoxic and hypoxic conditions. GO terms enrichment analysis was
performed on these proteins using GOrilla (32).
Multiple Reaction Monitoring to Quantify 20S Proteasome Sub-
units—Dried peptide samples were resuspended in a solution con-
taining 2% acetonitrile, 0.05% TFA, to obtain a final concentration of
1 g/l. To obtain data for the whole set of peptides/transitions,
samples were injected twice as the list of transitions was split into two
methods. The sample (2.5 l, about 2.5 g protein equivalent) was
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loaded onto the system and analyzed on a hybrid triple quadrupole-
ion trap mass spectrometer 6500 QTrap (AB Sciex, Framingham, MA)
equipped with a nanoelectrospray ion source coupled to an Ultimate
3000 system (Dionex) for chromatographic peptide separation. Sep-
aration was achieved using a 60 min gradient from 0 to 50% of
solvent B (80% acetonitrile, 0.2% formic acid) at a flow-rate of 300
nL/min. Spray voltage was set to 2500 V, curtain gas to 35 psi,
nebulizer gas to 5 psi, interface heater temperature to 75 °C, and
cycle time to 3 s (3.1620 s and 3.0380 s for the two methods).
Peptides were loaded onto a C18 precolumn (300 m inner diame-
ter  5 mm; Thermo Scientific) at 20 l/min in 2% acetonitrile, 0.05%
trifluoroacetic acid. After 5 min of desalting, the precolumn was
switched online with the analytical C-18 column (75 m inner diam-
eter  50 cm; in-house-packed with Reprosil C18) and equilibrated in
solvent A (5% acetonitrile, 0.2% formic acid).
Proteotypic peptide sequences were selected based on results of
previous discovery experiments (33–35) and by referring to the golden
rules (16) (i.e. considering isoforms, variants, PTMs reported on pro-
tein sequence or possibly artifactually-induced by sample handling,
or missed cleavages, observed in Protein (UniProt) or MS databases
(PeptideAtlas)). To achieve maximal sensitivity, collision energies
(CEs) were optimized within a 6 V window around the CE value
recommended by Skyline software and based on the m/z of the
precursor. Final SRM transitions are given in supplemental Data S3.
Transitions could be unambiguously assigned thanks to the co-in-
jected isotope-labeled peptides. Samples were run in a blinded fash-
ion except for calibration curves, for which the lowest concentrations
were injected first. To check system suitability and performance
before injecting each batch of samples, Total Ion Current was tuned
(chromatographic solvent ions of m/z 50 to 1000) at 2000 Da/s scan
speed in Q1. Quality controls (QC) (20 fmol of tryptic digest of be-
tagalactosidase; transitions are given in supplemental Data S4) were
injected between each sample. Carry-over was checked by injecting
tryptic digests of 100 fmol, 500 fmol or 1000 fmol of isotopically
labeled sP20S and iP20S spiked in 2.5 g of HeLa, then one QC
sample, and finally a blank sample (the maximum carry-over observed
was less than 0.01%). Quantitative reproducibility over time was
checked based on signal intensities for heavy transitions (maximum
deviation of 50% allowed); injection batches were generally carried
out over periods of less than 1 week.
Quantitative data analyses were performed using Skyline-Daily
open-source software (36). Area values for all transitions were first
extracted automatically by the software, then checked manually and
adjusted if necessary (i.e. exclusion of data points if S/N  10). Light
transition (L) peak area signals were then normalized with respect to
their labeled counterparts (H) (after correction by considering the 95%
incorporation rate for R(13C6) and K(
13C6) in labeled sP20S and
iP20S). For each transition, technical replicates of injection (typically
three) were averaged. Ratios (L/H) of all the transitions used to assay
a given protein or for total 20S proteasome (details in supplemental
Data S3) were then averaged. The amount of labeled reference mix
(containing equimolar concentrations of isotope-labeled sP20S and
iP20S) spiked into the biological sample before sample preparation
was then used to determine the absolute quantity of each proteasome
subunit or total 20S proteasome. For each transition, LOD and LLOQ
were experimentally determined by injecting heavy-isotope-labeled
sP20S and iP20S spiked at increasing concentrations in a HeLa
protein lysate and processed by the same method as applied to the
other biological samples. LOD and LLOQ values were calculated
using QuaSAR (37), which was implemented through the Skyline
interface (see supplemental Data S5).
Targeted MS measurements were highly multiplexed, and used to
quantify proteasome subunits across cell lysates, tissues and primary
cells of human origin. The assay developed used internal standards
for each analyte, to confidently detect and precisely quantify the
proteins of interest. Thus, the analyses meet the expectations of Tier
2 level.
Determining the Stoichiometry of the Six Major 20S Proteasome
Subtypes—The concentrations and stoichiometries of all proteasome
subtypes were determined as explained hereafter.
Total proteasome absolute quantity was calculated by averaging
the quantities of all 20S noncatalytic subunits (1–7; 3, 4, 6, 7)
(mean (1,2,3,5,6,7; 3,4,6,7) 3 Total P20S). A stoichiometry of two
noncatalytic subunits per 20S proteasome and a molecular weight of
700,000 g/mol were used in these calculations.
As 5 is integrated into the standard proteasome, its fraction
exclusively represents the fraction of standard proteasome (5 3
sP20S). Similarly, the level of 5t corresponds to the fraction of
thymoproteasome “5t P20S”, and can be obtained by subtracting
the sum of 5 and 5i levels from the total amount of 20S proteasome
(Total P20S  5  5i  5t 3 5t P20S). As the 2i subunit is
integrated into both the immunoproteasome and the thymoprotea-
some, the difference in its quantity compared with 5t can be used to
determine the fraction of immunoproteasome (2i  5t 3 iP20S).
The 1i-containing proteasome subtypes correspond to immunopro-
teasome, thymoproteasome, and intermediate proteasome 1i 5i.
Thus, the quantity of 1i 5i P20S is equal to the difference in
abundance of 1i and 2i proteins because both immunoproteasome
and thymoproteasome contain 2i (1i  2i 3 1i5i P20S). 5i is
contained in the immunoproteasome and in both types of intermedi-
ate proteasomes (5i3 iP20S  5i P20S  1i5i P20S). Thus, the
amount of 5i P20S can be calculated as follows: 5i  5t  1i 
Total P20S  1i  5 3 5i P20S.
Finally, the spermatoproteasome level can be determined from the
quantity of the 4s isoform (PSA7L protein _PSMA8 gene) by sub-
tracting the abundance of the 4 subunit from the total 20S protea-
some content (using specific peptides of the PSA7 isoform_PSMA7
gene as detailed in supplemental Fig. 8A) (sP20S  43 4s P20S).
Thus, the absolute amounts of noncatalytic subunits, as well as
those of the catalytic 2i, 5, 5i and 1i subunits determined by the
SRM method were used to calculate the proportions of the six main
20S proteasome subtypes, as summarized below:
mean (1,2,3,5,6,7; 3,4,6,7) 3 Total P20S
5 3 sP20S
Total P20S  5  5i  5t3 5t P20S
2i  5t 3 iP20S
1i  2i 3 1i5i P20S
P20S  1i  5 3 5i P20S
sP20S  4 3 4s P20S
Experimental Design and Statistical Rationale—
SRM Analyses—All statistical analyses were performed on at least
three independent biological replicates. For each biological replicate,
results from at least two injection replicates were averaged. Proba-
bility values (p) were determined by one-way and two-tailed analysis
of variances (ANOVA). Differences were statistically significant at
confidence levels of 95% (*), 99% (**), or 99.9% (***).
Coefficients of variation were calculated as ratios of the standard
deviation over the mean of the values and are expressed as a per-
centage. Accuracy was determined as the ratio of the difference of
the experimental value and the reference value over the reference
value and is expressed as a percentage.
Label-free MS Analyses (Fig. 3B and supplemental Fig. 11)—The
“human tissue extract” data set contains mass spectrometry results
from the analysis of 11 different human tissues analyzed in triplicate,
corresponding to 33 raw files. The “ADSC” data set contains mass
spectrometry results from the analysis of three different patients
under two different oxygen percentages used for cell culture, sam-
ples were analyzed in triplicates, and thus produced 18 raw files.
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Quantitative proteomic analysis was performed on the normalized
LFQ intensities from the “proteinGroups” Table in the MaxQuant
output.
The data sets corresponding to the mass spectrometry analyses
presented in this study have been deposited in the following reposi-
tories: PRIDE (Project accession: PXD011894) for label-free MS anal-
yses, and PeptideAtlas (Dataset identifier: PASS01219) for targeted
MS analyses. The detailed descriptions of all analyses (raw and
processed file names, sample name, biological replicate number, MS
technical replicate number, corresponding figure) are summarized in
supplemental Data S8.
RESULTS
Design and Validation of the SRM Assay to Determine 20S
Proteasome Status—The method aimed to simultaneously
determine the absolute 20S proteasome quantity and subtype
stoichiometry in a single assay. To achieve this goal, we
designed a workflow combining IDMS and SRM to exploit its
multiplexing capacity, sensitivity and robustness. In terms of
total 20S proteasome absolute quantification, preliminary op-
timizations were used to select the most appropriate mode of
internal standardization to correct for a range of experimental
biases (Fig. 1B; supplementary Information I-1). As detailed in
supplementary Information I-1 and supplemental Figs. S1–S5,
the isotope-labeled whole proteasome complex added to bi-
ological preparations clearly provide a much more robust
absolute quantification method than spiking with individual
isotope-labeled “AQUA” proteotypic peptides for each 20S
subunit. Indeed, despite good analytical performance in terms
of reproducibility and linearity, absolute quantification using
AQUA peptides technology lacked accuracy. This critical is-
sue was overcome by using the absolute SILAC quantification
method. We produced and affinity-purified isotope-labeled
standard proteasome and immunoproteasome to obtain
highly pure standards with a high level of subtype purity (min
99%) and with an excellent isotopic incorporation rate (min
95%) (supplementary Information I-1, supplemental Figs. S3–
S4). The optimized quantification method then consisted in
the distribution of a reference mixture of 20S proteasome
subunits with carefully-controlled stoichiometry into protein
lysates (Fig. 1B). After digestion of proteins using trypsin, an
SRM method including at least one peptide sequence (with
three associated transitions for each light and labeled surro-
gate) for the 11 noncatalytic subunits (1–7; 3, 4, 6, 7)
(supplemental Data S3) was applied. With this method, abso-
lute quantification of total 20S proteasome was achieved in
protein lysates of eight different human cell lines of diverse
origins (HEK 293T, HCT116, RKO, U937, HeLa S3, NB4,
KG1a, and MRC5). 20S proteasome concentration deter-
mined by the SRM method was compared with those ob-
tained with the reference ELISA method (Fig. 2A). A high
correlation was found between the two methods (coefficient
of determination  0.98; slope  1.01). Altogether, these data
demonstrate that the newly-developed method is suitable for
absolute quantification of 20S proteasome in human cell
lysates.
Next, we implemented the method to detect the six
standard and immune-specific catalytic subunits of the 20S
proteasome (1, 2, 5, 1i, 2i, 5i), as the absolute quan-
tification of these subunits is required to determine the stoi-
chiometry of the different 20S proteasome subtypes present
in biological samples (Fig. 1). Two to three proteotypic peptide
sequences (and three or four associated transitions for each
light and labeled surrogate) were carefully chosen, paying
attention to favoring wide distribution over the protein se-
quence. Transitions and detection were then optimized for the
six catalytic subunits. In total, the final method to quantify all
 and  subunits comprised 206 independent MS transitions
(103 “light” transitions and 103 “heavy” transitions corre-
sponding to heavy surrogate peptides) associated with opti-
mized dwell times and voltages for detection by the mass
spectrometer (supplemental Data S3). The method to quantify
of the absolute levels of all six 20S proteasome catalytic
subunits was validated by taking advantage of the known
stoichiometry of incorporation of catalytic subunits into the
20S proteasome (supplementary Information I-2). Based on
the excellent accuracy (97 	 2%) and variability (CVs below
15%) of the method to measure the absolute levels of cata-
lytic subunits (supplementary Information I-2 and supplemen-
tal Fig. S7B–S7D), these data were further used to determine
changes in the stoichiometries of the four 20S proteasome
subtypes observed in a model of IFN-treated HeLa cells
(sP20S, 5i P20S, 1i5i P20S, and iP20S - no 5t P20S nor
4s P20S detected) (as detailed under “Experimental proce-
dures”) (Fig. 2B). As expected, iP20S was highly and signifi-
cantly increased (by a factor of 12), becoming the major
proteasome subtype after 96 h stimulation with IFN, whereas
sP20S levels dropped by nearly 3-fold (Fig. 2B). Strikingly, the
two intermediate 20S immunoproteasome subtypes, 5i
P20S and 1i5i P20S, which each represented around 10%
of the total 20S present, did not vary significantly after the
cytokine stimulation. This interesting result shows that the
main impact of IFN stimulation on the composition of pro-
teasome complexes is the progressive replacement of the
sP20S by the iP20S subtype.
Determining the Stoichiometry of 20S Subtypes in Human
Tissues of Broad Origins—Next, we applied the method to
determine the absolute quantities and precise stoichiometries
of 20S proteasome subtypes in 11 protein lysates extracted
from human tissues of broad origins (Fig. 3). In most tissues,
the proteasome represented 0.2 to 1% of the total protein
present (Fig. 3A). A shotgun label-free LC-MS/MS proteomics
analysis exclusively identified and quantified 4s and 5t in
testes and thymus samples, respectively, confirming their
tissue-specificity (4), whereas the immunocatalytic subunits
(5i, 1i, and 2i) were much more widely distributed across
tissues (Fig. 3B). The stoichiometries of the six major 20S
proteasome subtypes (Fig. 1A) were determined based on the
absolute quantities of  and  subunits measured using the
optimized method (as explained under Experimental Proce-
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dures). The absolute level of the catalytic 5t subunit provided
the abundance of the thymoproteasome (Fig. 1A). Because
this protein is not incorporated into labeled sP20S and iP20S
internal standards, the absolute quantity of 5t was deduced
from absolute amounts of total P20S, 5 and 5i (Fig. 3C).
Similarly, the 4s subunit (PSMA7L protein) which is repre-
sentative of the spermatoproteasome could not be directly
quantified. Although 4 and 4s are very similar in sequence,
three peptide sequences that are specific to the PSMA7 pro-
tein (4) were detectable and were used to distinguish be-
tween the two isoforms (supplemental Fig. S8A). The absolute
level of 4s was deduced from standard P20S and 4 con-
tents (Fig. 1B, Experimental Procedures). As in the shotgun
assay, proteotypic peptides corresponding to the thymopro-
teasome and spermatoproteasome were only observed in
thymus and testes tissues, respectively, (Fig. 3B) and these
two 20S proteasome subtypes represented only 20 and 12%
of the total proteasome pool in these organs, respectively
(Fig. 3C). A principal component analysis (PCA) biplot based
on catalytic subunit composition (Fig. 3D) grouped brain,
FIG. 1. Workflow for determination of total 20S proteasome absolute quantity and stoichiometry by LC-SRM. A, Schematic repre-
sentation of the six main 20S proteasome subtypes with different sets of subunits. The sP20S is the most abundant 20S subtypes in most cell
types. The 20S proteasome subtypes containing at least one immunocatalytic subunit are predominantly observed in immune cells but can also
be induced in response to inflammatory cytokines. Other 20S proteasome subtypes are tissue-specific, like the thymoproteasome (5t P20S)
and the 4s proteasome (4s P20S) which have been observed in the thymus and in reproductive cells like testes, respectively. B,
Determination of total 20S proteasome quantity and 20S subtypes stoichiometry in Human cell lysates or tissues using SRM. Endogeneous
proteasomes contained in biological samples were digested with trypsin. The SRM approach was designed to quantify in a multiplexed manner
a set of proteotypic peptides corresponding to  subunits, as well as  catalytic and noncatalytic subunits. Isotope-labeled standard and
immunoproteasome complexes were used as internal standards in the final method. They were spiked in the biological sample at equimolar
quantities before the tryptic digestion. Alternatively, heavy “AQUA” peptides were added to the endogeneous peptides lysate after
tryptic digestion. At least three endogeneous peptides, and three transitions per peptide were analyzed. Thanks to internal normalization
with the isotopically-labeled peptides transitions, the absolute quantity of selected  and  noncatalytic subunits as well as of  catalytic
subunits were obtained and used to compute the absolute quantities of total 20S proteasome and to assess the stoichiometries of the six
main 20S proteasome subtypes in biological samples. Details are provided in the Experimental Procedures section and in Experimental
section.
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muscle, heart, and testes tissues as they almost exclusively
contain standard proteasome  subunits (1, 2, and 5).
Bone marrow, spleen, and thymus were observed on the
opposite side of the graph because they contain high levels of
1i, 2i, and 5i immunosubunits. Interestingly, intermediate
20S subtypes (5i P20S and 1i5i P20S) were only detected
in low abundance (less than 10% of the total 20S proteasome
pool) in bone marrow and spleen, suggesting that the immu-
noproteasome is the most important proteasome subtype for
antigen processing among immunosubunit-containing sub-
types. Liver, colon, ovary and lung tissues were placed at an
intermediary position on the PCA graph (Fig. 3D), with 50 to
70% of immunosubunit-containing 20S proteasome subtypes
(Fig. 3C).
Interestingly, the absolute amount of the 4 subunit, mea-
sured using peptides common to PSMA7 and PSMA7L pro-
teins (supplemental Fig. S8A–S8B), was stoichiometric and
highly correlated with the total 20S proteasome amount
(measured using the  and  noncatalytic subunits, apart from
4) both in the panel of eight cell lines (R2  0.97; slope 
0.99) and in tissues of diverse origins (R2  1.00; slope 
1.01) (supplemental Fig. S8C–S8D). This result once again
FIG. 2. Final validation of the LC-SRM method to determine absolute quantity of total 20S proteasome and to precisely and
accurately monitor the dynamics of 20S subtypes stoichiometries. A, Correlation curve between the 20S proteasome concentration
measured by the ELISA reference method and the one determined by LC-SRM in a panel of eight human cell lines (HEK 293T, HCT116, RKO,
U937, HeLa S3, NB4, KG1a, and MRC5). The LC-SRM method was based on the isotopic dilution of equimolar amounts of in-house
isotopically-labeled sP20S and iP20S (R(13C6) and K(
13C6)) in each cell line protein lysate. One peptide sequence (and three transitions for the
light and the heavy surrogate) and three peptide sequences were analyzed for noncatalytic subunit (1–7; 3,4,6,7) and catalytic subunits
(1,2,5,1i, 2i, 5i), respectively (see supplemental Data S3 for more details on peptides and transitions). An equivalent of 2.5 g total proteins
containing the sP20S and iP20S heavy internal standard mix were injected on column and analyzed by SRM, as detailed in the Experimental
Procedures. Three biological replicates (and three technical replicates) were analyzed to obtain statistics. The total proteasome concentrations
measured in the initial protein lysates are presented. B, Dynamics of 20S subtypes stoichiometries upon IFN stimulation of HeLa cells. The
absolute quantities of each of the six catalytic subunits measured by the LC-SRM method were computed to calculate the stoichiometries of 20S
proteasome subtypes as detailed under Experimental Procedures. HeLa cells were stimulated for 0, 24, 72, or 96 h with IFN and the SRM method
used to quantify proteasome subunits in each total cell lysate obtained at each time point of cytokine stimulation. Peptides sequences, transitions
and applied voltages are detailed in supplemental Data S3. Three biological replicates were analyzed to obtain statistics. The sum of the
stoichiometries of the four 20S proteasome subtypes is very close to the expected value of 100 (obtained from independent measurement of total
20S proteasome absolute quantity). C, Method variability (CV %) and accuracy (%) calculated with data obtained from IFN-stimulated HeLa cells.
Accuracy was calculated from comparison of total 20S proteasome quantity obtained from noncatalytic subunits (reference values) and from
1/1i, 2/2i, and 5/5i couples of catalytic subunits (experimental values) (n  36). Accuracy were computed as follow: accuracy 
(experimental value  reference value)/reference value  100. Method variability: Coefficients of variation on all independent measurements (n 
24). Details on stoichiometry determination of 20S proteasome subtypes are provided under Experimental Procedures.
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confirms the accuracy and precision of the method developed
while also emphasizing the need for absolute quantification to
detect perturbations in proteasome subunit expression or
incorporation of subunits into mature proteasomes. It also
indicates that this broad panel of normal and tumor human
cells do not contain the noncanonical alternative 4-4 20S
proteasome complex in which a second copy of 4 occupies
the position normally held by 3 (38, 39).
The abundance of some proteasome subunits measured
using our optimized MRM assay was compared with mRNA
expression data retrieved from the human protein atlas data-
base (40) in corresponding tissues (supplemental Fig. S9).
Although positive correlations were observed between some
proteins and mRNA molecules abundances, these results
suggest that measuring mRNA levels are not suitable when
seeking to predict protein expression levels for 20S protea-
some subunits in human tissues.
Proteasome Status Is Affected by Priming ADSCs with IFN
During Their Ex Vivo Expansion—Thanks to their immunosup-
pressive properties, MSCs are considered a promising tool for
cell therapy. Much effort has been directed toward enhancing
MSCs activity by treatment with IFN. However, any ex vivo
modifications may also fundamentally alter the cells, and un-
derstanding determinants that affect their immunomodulatory
activity is essential if we are to develop effective MSC strat-
egies. MSCs obtained from patients must be expanded ex
vivo if they are to be used in the clinic, and this process must
be carefully controlled (41). Recently, we reported a decrease
in the immunosuppressive properties of ADSCs cultured up to
the senescent stage and demonstrated that this effect was
FIG. 3. The method is able to precisely and accurately monitor 20S proteasome absolute quantities and subtypes stoichiometries in
a panel of human tissues. A, Proteasome 20S absolute quantity (% w/w total proteins) measured by the LC-SRM method and 20S
Proteasome chymotrypsin-like activity measured by degradation of LLVY-AMC peptide, in a panel of 11 human tissues. B, Label-free relative
quantification of tissue-specific 20S proteasome subunits by label-free LC MS/MS reveals the tissue-specificity of 4s and 5t subunits but
not the one of immunocatalytic subunits. Relative abundances of each subunits across the tissues are represented. The highest abundance
is arbitrarily set to 1. C, Stoichiometries of the six proteasome 20S subtypes in different Human tissue determined by the LC-SRM method.
Details on stoichiometry determination of 20S proteasome subtypes are provided under Experimental procedures. D, Biplot Principle
Component Analysis of 11 human tissue samples (3 replicates per tissue) based on 20S proteasome catalytic subunits composition. The
dashed circles represent the main clusters observed depending on content on standard (1, 2, 5) or immuno (1i, 2i, 5i) subunits.
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the result of proteasome-mediated indoleamine 2,3 dioxyge-
nase (IDO) degradation (42). Priming of MSCs with IFN has
been shown to extensively potentiate their therapeutic activity
(43, 44) but, to our knowledge, and although proteasome
functions cover a broad spectrum of biological functions, the
proteasome status has never been assessed in this context.
When used to measure the consequences of IFN-stimulation
of ex vivo-expanded patient-derived ADSCs on proteasome
status (Fig. 4A), our method revealed no major changes in the
total 20S proteasome quantity (Fig. 4B). However, a massive
replacement of standard catalytic subunits by their immuno-
logical counterparts was clearly observed (Fig. 4C), resulting
in a strong shift from the standard to the immunoproteasome
subtype (Fig. 4D). Indeed, although the standard subtype
represented 75% of the 20S proteasome pool when ADSCs
were expanded in an IFN-free medium, this proportion was
decreased to 25% after 4 days’ culture in the presence of the
cytokine (Fig. 4D). The massive induction of the immunopro-
teasome by cytokine stimulation is likely to have a consider-
able impact on the repertoire of degraded proteins and anti-
genic peptides loaded onto major histocompatibility complex
class I (MHCI) molecules.
Expansion of ADSCs Under Different O2 Concentrations
Affects 20S Proteasome Status and Their Capacity to Differ-
entiate—Conventionally, MSC culture for clinical applications
is performed under normoxic conditions (21% oxygen ten-
sion), even though oxygen levels within tissues are typically
much lower (hypoxic) than these standard culture conditions.
Therefore, oxygen tension represents an important environ-
mental factor that may affect how MSCs perform in vivo.
However, the impact of hypoxic conditions on distinct mes-
enchymal stem cell characteristics, such as the proteasomal
status, remains unclear.
We applied our method to analyze the 20S proteasome
status after 10 days of ADSCs expansion under three different
oxygenation concentrations: 1%, 5%, and 20%. Interestingly,
proteasome abundance, proteolytic activity and composition
were all affected by dioxygen levels (Fig. 5A–5C). Indeed,
when comparing the effect of ADSC expansion in hypoxic or
normoxic conditions (1% versus 20% O2 levels), we detected
a significant increase in total 20S proteasome abundance
alongside a nearly 2-fold significant upregulation of the three
immunoproteasome catalytic subunits (Fig. 5A and 5C). Both
changes probably account for the higher 20S proteasome
chymotrypsin-like activity measured following culture in nor-
moxic conditions (Fig. 5B). Indeed, structural differences in
active sites account for the higher chymotrypsin-like activity
of the 5i subunit of the immunoproteasome compared with
its 5 standard counterpart (5, 45). Moreover, the relative
abundance of 20S proteasome-associated PA28 activator
is decreased in hypoxia compared with normoxia (p  0.02)
whereas the O2 level had no significant impact on the level of
FIG. 4. Proteasome status is affected by priming ADSCs with IFN during their ex vivo expansion. A, Workflow for the determination of the
effect of priming of ADSCs with interferon- on their 20S proteasome status, using the LC-SRM method. Primary cells obtained from two patients
were used for the study. B, Proteasome 20S absolute quantity (% w/w total proteins) measured by the developed LC-SRM method in ADSCs
obtained from patients (n  2 biological replicates - 3 technical replicates). C, Fold change in the six catalytic subunits of the 20S proteasome during
IFN stimulation. ADSCs were cultivated in the presence of the cytokine (100 ng/ml). Absolute quantities of the catalytic subunits were determined
by the developed LC-SRM approach and fold changes are calculated relative to time 0h (n  2 biological replicates  3 technical replicates). D,
Dynamics in the stoichiometries of 20S proteasome subtypes during IFN stimulation of primary ADSCs derived from patients (n  2 biological
replicates  3 technical replicates). Calculations are detailed under Experimental procedures.
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association of the other 20S CP regulators (supplemental Fig.
10B). This last observation further supports the increase
measured in immunoproteasome subtype in normoxic com-
pared with hypoxic conditions as PA28 is known to pref-
erentially associate with the 20S immunoproteasome variant
in cellulo (34).
Overall, in the absence of IFN in the culture medium, the
major proteasome subtype observed in ADSCs was the
standard proteasome, which represented 60 to 80% of
the total proteasome pool, depending on patient and O2 level
(supplemental Fig. S9A). Given the massive induction of im-
munoproteasome upon exposure to the pro-inflammatory cy-
tokine (Fig. 4C) and the absence of immune cells in the ADSC
culture medium, the inter-individual differences observed in
immunoproteasome content might result from variability in the
inflammatory context before surgery. Immunoproteasome
subunits have been shown to be required for adipocyte dif-
ferentiation (29). Accordingly, our data indicate that high lev-
els of immunoproteasome correlate with high adipogenic po-
tential at 20% O2, and the reverse under hypoxic conditions
(Fig. 5D). Strikingly, pharmacological inhibition of the immu-
noproteasome using the ONX-0914 inhibitor (46) leads to a
marked decrease in the capacity of ADSCs to differentiate
into adipocytes, which confirms previous observations in the
PSMB8 KO mice (29) using an orthogonal method.
To get a broader picture of the effect of O2 levels on the
proteome of ADSCs, a whole proteome analysis was per-
formed on ADSCs grown under normoxic or in hypoxic con-
ditions (1% of O2). Importantly, a new cohort of three patients
was used to obtain this new biological material. Out of 3624
proteins identified and quantified, 67 proteins were found at
increased levels in hypoxic conditions and 129 were over-
represented in normoxic conditions (supplemental Fig. S11
and revised supplemental Data S7). All three immunocatalytic
FIG. 5. Expansion of ADSCs in different O2 levels affect 20S proteasome status and ADSCs’ capacity to differentiate. A, Proteasome
20S absolute quantity (% w/w total proteins) measured by the LC-SRM method in five patients derived primary ADSCs cultivated at three
different levels of O2 (1%, 5%, and 20%). B, Proteasome 20S chymotrypsin-like activity measured by the in vitro degradation of the LLVY-AMC
peptide by proteasome in ADSCs lysates after cultivation in three different levels of O2 (1%, 5%, and 20%) (n  5 patients  3 technical
replicates). C, Relative content of standard and immuno catalytic 20S proteasome subunits measured by the method in five patients derived
primary ADSCs cultivated at three different levels of O2 (1%, 5%, and 20%). D, Differentiation potential of human ADSCs from different patients
under different levels of O2 (1%, 5%, and 20%). The immunoproteasome inhibitor ONX-0914 alters the differentiation capacity of ADSCs at
5 and 20% O2 concentrations. Adipogenic differentiation is indicated by Oil red O staining.
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subunits were increased under normoxic conditions (fold in-
crease of 1.6 to 1.9) although statistical significance was only
reached for 1i and 2i (p value  0.05). As discussed above
(supplemental Fig. S7), this apparent discrepancy can easily
be explained by the lower precision of label-free quantification
results compared with SRM quantification data.
Functional analysis based on GO Biological processes re-
vealed the most significant pathway related to the proteins for
which abundance was modified both under hypoxic and nor-
moxic conditions to be the “oxidation-reduction” pathway
(FDR  1.2E-06 and 5.9E-03 for proteins upregulated in hy-
poxic and in normoxic conditions, respectively). This result
was to be expected following a change in O2 levels from 20%
to 1%. Other enriched GO Biological pathways included “re-
sponse to oxidative stress” (FDR  4.2E-02) in the proteins
that were more abundant in normoxic conditions. This path-
way is particularly interesting as the immunoproteasome has
been associated with responses to oxidative stress (47–49).
ADSCs were also shown to negatively regulate oxidative
stress in vivo (50) and notably through Nrf2 which is one of the
main transcription factors involved in controlling oxidative
stress. In our whole-proteome analysis, we observed that
NQO1 (2-fold increase, p value  0.02), one of the best-
known targets of Nrf2 (51), was increased under normoxic
compared with hypoxic conditions. Reactive oxygen species
seem to play an important role in adipocyte differentiation
(52–54). A function of the immunoproteasome related to
ADSC differentiation could be the clearance of proteins hav-
ing undergone oxidative damage, when this type of damage
accumulates it could be toxic for the cell. Significantly, 25 of
the proteins for which overall abundance differences were
detected are functionally related to the “cell differentiation”
GO Biological Process (FDR  1.4E-02 for proteins over-
represented in cells grown under hypoxic conditions). Among
these, 16 were increased in the hypoxic cells whereas 9 were
decreased. These proteins are listed in supplemental Data S7
(4th sheet). Given the importance of the immunoproteasome
in regulating ADSC differentiation when stimulated with dexa-
methasone, and because our results clearly demonstrate that
the immunoproteasome is increased under normoxic com-
pared with hypoxic conditions, it is tempting to speculate that
some of these deregulated proteins might be direct or indirect
targets of the immunoproteasome. In particular, Transforming
growth factor-beta-induced protein ig-h3 (TGFBI/BGH3) and
Plasminogen activator inhibitor 1 (PAI1) were both increased
in our hypoxic cells (4.1- and 2.9-fold increase, respectively,
with p values of 8.5E-4 and 0.03, respectively), and these
proteins are known to be target genes of TGF1, a pathway
required for hypoxia-mediated inhibition of adipocyte differ-
entiation (55). Of course, further experiments will be neces-
sary to confirm that these proteins are downstream players of
the immunoproteasome affecting the adipogenic potential of
ADSCs.
In conclusion, after as few as 10 days of ADSCs expansion
under different dioxygen levels, the method developed could
detect mild but still significant changes in 20S proteasome
status, and variations in the level of 20S immunoproteasome.
This change in proteasome composition might be causal for
the observed O2-induced variations in differentiation potential
of ADSCs even though further investigation will be required to
determine the precise mechanisms.
DISCUSSION
This study aimed to develop an assay to determine subunit
absolute quantity and stoichiometry within a highly heteroge-
neous macromolecular protein complex, the 20S proteasome.
To achieve this goal, a robust, accurate and sensitive absolute
quantification method with multiplexing ability had to be de-
veloped to allow the absolute quantification of the 19 different
subunits of the 20S proteasome in a single assay.
Absolute quantitation based on IDMS using the SRM scan-
ning mode suits the requirements for multiplex detection and
is also recognized for its specificity, sensitivity, and accuracy
(16, 17). Because many proteasome subunits had to be ana-
lyzed, we first used the most straightforward IDMS proteo-
mics strategy, the AQUA (18) method, which involves spiking
various isotope-labeled synthetic peptides into samples as
internal standards. Although mainly used for the absolute
quantification of monomeric proteins, the AQUA method has
also been successfully applied to assess the sub-stoichio-
metric incorporation of the Rpn13 ubiquitin receptor within the
26S proteasome (56). Our AQUA peptide sequences were
carefully chosen to meet the requirements for IDMS analysis
of proteins (16) and, when tested in simple or more complex
biological matrices, they provided good linearity in signal
response, low variability, and adequate sensitivity. These an-
alytical performances explain why the AQUA technology was
so rapidly adopted for the LC-SRM validation of protein bio-
markers in various biological matrices (16, 17). However, we
noted a defect in trueness that was easily detected in our
system because noncatalytic proteasome subunits are ex-
pected to be present at equimolar stoichiometry. Responses
were observed to be highly dependent on peptide sequences,
probably because of incomplete enzymatic digestion of the
protein of origin; other reasons for the discrepancy observed
could be incomplete peptide solubilization, peptide instability,
or artifactual chemical modifications. Thus, isotope-labeled
peptides could not be used to accurately assess proteasome
subtype stoichiometry unless laborious optimizations were
undertaken (19). Several IDMS methods based on the use of
isotope-labeled protein standards like PSAQ (21), absolute
SILAC (22), PrEST (23), or TAQSI (25) were developed to
overcome the issues of the AQUA methodology. To the best
of our knowledge, none of these has yet been applied to
determine protein complex stoichiometry. To achieve this
goal on highly heterogeneous 20S proteasome complex, we
optimized a workflow relying on SILAC-based absolute
LC-SRM Quantification of 20S Proteasome for ADSCs Expansion
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quantification. A reference mixture containing equimolar con-
centrations of both isotope-labeled and purified 20S stand-
ard- and immuno-proteasome subtypes was produced, qual-
itatively and quantitatively assessed, and spiked into protein
lysates extracted from cell cultures or tissues. After protein
digestion, the SRM method was optimized for carefully cho-
sen proteotypic peptides. In this approach, use of a whole
isotope-labeled protein as internal standard represents a clear
advantage over the PrEST approach (23) because all proteo-
typic peptides can theoretically be used for quantification.
This method was validated by comparison with the reference
ELISA method for total 20S proteasome absolute quantifica-
tion in a broad range of biological samples.
Although 20S and 26S proteasome complexes can be rou-
tinely quantified using different ELISA assays (6, 10–14, 33),
this technique lacks the multiplexing capacity to assess the
complete diversity of proteasome subtypes because up to 19
different protein chains can be incorporated into the 20S
proteasome macromolecular assembly (Fig. 1A). Moreover, to
our knowledge, the precise stoichiometries of tissue-specific
5t- and 4s-containing 20S proteasome subtypes have
never yet been determined. Using our optimized assay, for the
first time, we accurately quantified the stoichiometry of the
tissue-specific thymoproteasome and spermatoproteasome;
their low levels in thymus and testes tissues (20 and 12% of
the total 20S proteasome pool, respectively) support findings
in previous reports showing that 5t and 4s are detected in
a subpopulation of cells in these two organs (4, 58).
Then, we demonstrated that our method could also pre-
cisely monitor changes in 20S proteasome  catalytic subunit
composition following IFN-activation of HeLa cells. We took
advantage of the known stoichiometry of  catalytic subunits
in the 20S proteasome to assess the trueness of the method,
which exceeded 96%. In comparison, the TOP3 label-free
quantification approach barely achieves 78% accuracy after
discarding outliers arising from unrepresentative peptides.
Converting peptide abundance into protein concentration re-
quires careful selection of peptide sequences and optimiza-
tion of SRM transitions (19) or, alternatively, the removal of
incoherent peptides from global MS1-based quantification
datasets, for instance using covariation of peptide abun-
dances (59). Thus, even if label-free MS1-based quantification
methods can be used to obtain a rough estimate of protein
complex stoichiometry, as previously reported (60–62), these
approaches are most appropriate for the high-throughput
determination of changes in the relative abundances of pro-
tein complex subunits (34, 35) or estimation of protein copy-
number without requiring spike-in standards (63).
MSCs obtained from bone marrow (BM-MSCs) or AT
(ADSCs) are promising tools for cell therapy in regenerative
medicine, to treat severe inflammatory and autoimmune dis-
eases, or to prevent transplant rejection (64). Cells must be
expanded ex vivo to obtain enough numbers for use in ther-
apy. Thus, culture conditions must be carefully controlled
both for safety issues and to optimize therapeutic effective-
ness. Using our method, we showed that pre-stimulation of
ADSCs with IFN and increasing O2 levels both affect the
status of the 20S proteasome during ex vivo expansion of
primary ADSCs. In both cases, changes in proteasome com-
position were observed, an increase in immunoproteasome
stoichiometry. These results emphasize the high plasticity of
the 20S proteasome when exposed to external stimuli, but
also the multiple biological roles played by the immunoprotea-
some subtype. IFN is known to induce the immunoprotea-
some through the formation of new proteasome particles incor-
porating immunocatalytic subunits in place of the standard
ones. Pre-stimulation of both BM-MSCs and ADSCs with pro-
inflammatory cytokines, IFN, has been shown to increase their
immunosuppressive properties (43, 64, 65), by increasing re-
lease of several soluble immunosuppressive factors, in particu-
lar kynurenine, a product of indoleamine 2,3-dioxygenase (IDO)
activity (65). Moreover, both BM-MSCs and ADSCs are antigen
presenting cells (64) and, when exposed to IFN, they upregu-
late expression of HLA class I molecules on their surface. This
response protects them from NK-mediated lysis (43, 66), and
promotes their immunomodulatory effects. Strikingly, both
mechanisms linked to the immunosuppressive properties of
MSCs are affected by proteasome status. Indeed, a shift from
standard to immunoproteasome considerably increases the
production of MHC class I-binding peptides in vivo (67) and IDO
is known to be a proteasome substrate (68). Proteasome-me-
diated degradation of IDO was recently reported to explain the
reduction in immunosuppressive potential observed in clinical-
grade expanded MSCs which had reached replicative senes-
cence (42). Mechanistically, IFN is known to increase IDO
protein via transcriptional activation (69) but it is also responsi-
ble for a strong induction of the immunoproteasome-PA28
complex, a proteolytic system functioning in the absence of
ubiquitination (67). As IDO is degraded through the ubiquitina-
tion-dependent SOC3-proteasome pathway (68), the increase
in ubiquitin-independent degradation triggered by IFN might
constitute a mechanism further promoting IDO stabilization in
this physiological context.
In addition to its major role in antigen processing, the im-
munoproteasome seems to degrade oxidized proteins more
efficiently than the standard 20S CP (70, 71). De novo syn-
thesis of 20S proteasome and of immunoproteasome is cru-
cially important for maintaining efficient proteostasis in oxida-
tive stress conditions (49). The evidence provided here of low
total proteasome content and an absence of immunoprotea-
some in brain probably accounts for the previously reported
higher sensitivity of brain tissues to oxidative stress (72).
Activation of the immunoproteasome and autophagy occur
during the early stages of ESC differentiation, to allow degra-
dation of damaged proteins and avoid their transmission to
differentiated cells (27). Moreover, recent findings indicate
that the immunoproteasome is required for differentiation of
adipocytes (29) and skeletal muscle (28). In line with this
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requirement, our results demonstrate that ADSCs grown un-
der hypoxic conditions, had a lower immunoproteasome con-
tent and exhibited a lower differentiation potential than their
counterparts grown under 20% O2. In addition, our results
suggest that immunoproteasome activity is causal for the
change in adipogenic potential in normoxic conditions. Thus,
the significant increase observed in all three immunocatalytic
subunits and in overall proteasome activity in normoxia-cul-
tured primary ADSCs compared with the cells cultured in
hypoxic environments could reflect modulation of their ther-
apeutic capacities. Importantly, ADSCs are adult pluripotent
stromal stem cells isolated from white AT where O2 levels are
below 5% but they are routinely expanded ex vivo under 20%
O2. Manufacturing practices for ASC expansion must there-
fore be carefully optimized and controlled to maintain their
therapeutic capacity. The results from the approach devel-
oped here applied to primary ADSCs grown in conditions
close to real clinical production clearly demonstrate that IFN
and dioxygen levels could be key parameters in this process.
To conclude, the method presented here allows robust and
rapid determination of the complete status, i.e. absolute
quantity and stoichiometry, of a highly heterogeneous mac-
romolecular protein complex, the 20S proteasome, in various
human tissues and cells. When applied to primary ADSCs
expanded in different culture conditions, our results high-
lighted a high plasticity in proteasome composition and
abundance which might be related to modulation of the
ADSCs’ immunosuppressive and differentiation properties.
The method developed thus constitutes a sound approach to
complement immunophenotyping or other methods to moni-
tor protein markers (73) for the optimization and control of
manufacturing processes for ADSCs expansion. Knowledge
of proteasome composition is also of major interest for ther-
apeutic purposes. Indeed, upregulation or dysregulation of
immunoproteasome catalytic subunits have been observed in
several human diseases and disorders, such as inflammatory
and autoimmune diseases, cancer, diseases of the central
nervous system, and aging (74). For instance, mutations re-
ported in immunocatalytic subunits and the resulting defects
in 20S immunoproteasome assembly and activity observed
in PRAAS (Proteasome-Associated Autoinflammatory Syn-
drome) patients could be monitored using our method (re-
viewed in (75)). Our assay could also be of great interest when
seeking to assess patients before instigating immuno-therapy
as the efficacy of tumor antigen processing and presentation
is closely linked to levels of 20S immune-type proteasomes in
antigen presenting cells (75). Detection of increased concen-
trations of 20S proteasomes or changes in subtype profiles
could also be monitored in extracellular body fluids to di-
agnose and/or as a prognostic marker of various diseases
(76). In this context, a more specific targeting of the different
heterogeneous forms of the proteasome will lead, in the
long run, to more specific treatments generating fewer side
effects and less chemoresistance than caused by broad-
spectrum proteasome inhibitors (77). However, to design
such targeted therapies, tools to precisely determine pa-
tients’ proteasome status, like the one presented here, will
need to be developed.
More generally, the developed strategy could be extended to
assess the absolute level, dynamic, and heterogeneous nature
of many other biologically-relevant macromolecular systems
such as the human spliceosomal hprp19/CDC5L complex (19,
61), the nuclear pore complex (78), core ribosomal proteins (62),
or even host-pathogens interactions (79). These adaptations
would be more accurate than the peptide-based mass spec-
trometry methods currently used (61). The sole requirement for
this adaptation is that it must be possible to ectopically produce
and purify each individual subunit in carefully-controlled abso-
lute quantities with heavy-isotope incorporation.
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